JM
John D. Murphy
Also known as: Jack Murphy
EPAM Systems (United States), Foundation for Advanced Education in the Sciences, The University of North Carolina at Chapel Hill Gillings School of Global Public Health
Employment
-
EPAM Systems (United States) Data Scientist/Epidemiologist2024 - Present
-
Foundation for Advanced Education in the Sciences Adjunct Faculty2024 - Present
-
National Cancer Institute Division of Cancer Epidemiology and Genetics Postdoctoral Research Fellow2021 - Present
-
National Institute of Environmental Health Sciences Summer Intern2018 - 2018
-
Carolina Breast Cancer Study Graduate Research Assistant2017 - Present
-
National Cancer Institute Research Fellow2016 - 2017
Education
-
The University of North Carolina at Chapel Hill Gillings School of Global Public Health PhD2017 - 2021
-
Johns Hopkins Bloomberg School of Public Health MPH2015 - 2016
-
Columbia University Columbia College BA2009 - 2013
Projects & Funding
Projects & funding information is unavailable.
Publications (12)
- Prevalence of Cancer Risk Factors and their Association with Abnormal Cancer Screening Results in a Resource-constrained Tertiary Cancer Care Centre in Rural India Save
- Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom Save
- A Predictive Model of Noncardia Gastric Adenocarcinoma Risk Using Antibody Response to Helicobacter pylori Proteins and Pepsinogen Save
- Health, lifestyle and sociodemographic characteristics are associated with Brazilian dietary patterns: Brazilian National Health Survey Save
- Perineal Talc Use, Douching, and the Risk of Uterine Cancer Save
- Severe acne and risk of breast cancer Save
- Smoking and HIV in Sub-Saharan Africa: A 25-Country Analysis of the Demographic Health Surveys Save
- Epidemiology, risk factors, and opportunities for prevention of cardiovascular disease in individuals of South Asian ethnicity living in Europe Save
- The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature Save
- Updating the landscape of direct-to-consumer pharmacogenomic testing Save